多西环素与安慰剂治疗轻度甲状腺相关眼病12周对比:一项随机临床试验
这项安慰剂对照多中心随机双盲试验纳入中国5个中心的100例轻度甲状腺相关眼病患者,按1:1随机接受多西环素50 mg每日一次或安慰剂治疗12周。第12周复合指标改善率多西环素组为38.0%(19/50),安慰剂组为16.0%(8/50),差异22.0%(95%CI 5.0-39.0;P=.01)。作者认为结果支持考虑多西环素用于轻度甲状腺相关眼病,但需注意随访时间相对较短和队列规模。
要点
- 多西环素50 mg每日一次治疗12周,轻度甲状腺相关眼病改善率38.0%(19/50),安慰剂组16.0%(8/50)。
- 两组改善率差异22.0%(95%CI 5.0-39.0;P=.01),符合方案集分析结果相似。
- 仅记录到1例轻度胃酸反流不良事件,作者指出随访相对较短且队列规模有限。
核心结论
- 口服多西环素50 mg每日一次治疗12周,较安慰剂使轻度甲状腺相关眼病患者症状获得更大改善。
- 作者认为这些发现支持考虑多西环素用于轻度甲状腺相关眼病,但应考虑到随访时间相对较短和队列规模。
研究设计与样本
- 安慰剂对照多中心随机双盲试验,在中国5个中心于2013年7月至2019年12月纳入100例轻度甲状腺相关眼病(眶软组织轻度受累)患者。
- 148例患者接受资格评估,排除妊娠或哺乳、四环素过敏或未控制系统性疾病者后纳入100例,按1:1随机分配接受多西环素50 mg或安慰剂每日一次治疗12周。
- 主要结局为第12周较基线的改善率,采用眼睑孔径减小≥2 mm、眼球突出减小≥2 mm、眼球运动增加≥8°和Graves眼病特异性生活质量(GO-QOL)量表评分增加≥6分的复合指标评估。
- 通过参与者访谈和清点剩余药片核查用药依从性,并记录不良事件。
主要发现
- 多西环素组50例、安慰剂组50例;平均(SD)年龄36.7(9.1)岁,75例(75.0%)为女性,100例(100.0%)为亚洲人。
- 在意向治疗人群中,第12周改善率多西环素组为38.0%(19/50),安慰剂组为16.0%(8/50),差异22.0%(95%CI 5.0-39.0;P=.01)。
- 符合方案集敏感性分析结果相似:多西环素组39.6%(19/48)vs 安慰剂组16.0%(8/50),差异23.6%(95%CI 6.4-40.8;P=.009)。
- 两组除1例轻度胃酸反流外未记录到其他不良事件。
临床怎么用
- 原文未据此给出推荐。
- 作者认为这些发现支持考虑多西环素用于轻度甲状腺相关眼病,但应考虑到随访时间相对较短和队列规模。
局限性
- 作者指出应考虑到随访时间相对较短。
- 作者指出应考虑到队列规模。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Mild thyroid-associated ophthalmopathy (TAO) negatively impacts quality of life, yet no clinical guidelines for its treatment are available. Existing evidence supports the use of doxycycline in treating mild TAO. OBJECTIVE: To evaluate the short-term (12 weeks) efficacy of doxycycline in treating mild TAO. DESIGN, SETTING, AND PARTICIPANTS: In this placebo-controlled multicenter randomized double-masked trial, 148 patients were assessed for eligibility. After exclusions (patients who were pregnant or lactating, had an allergy to tetracyclines, or had uncontrolled systematic diseases), 100 patients with mild TAO (orbital soft tissue affected mildly) at 5 centers in China were enrolled from July 2013 to December 2019 and monitored for 12 weeks. INTERVENTIONS: Participants were randomly assigned 1:1 to receive doxycycline (50 mg) or placebo once daily for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was the rate of improvement at 12 weeks compared with baseline assessed by a composite indicator of eyelid aperture (reduction ≥2 mm), proptosis (reduction ≥2 mm), ocular motility (increase ≥8°), and Graves ophthalmopathy-specific quality-of-life (GO-QOL) scale score (increase ≥6 points). Adverse events were recorded. RESULTS: A total of 50 participants were assigned to doxycycline and 50 to placebo. The mean (SD) age was 36.7 (9.1) years; 75 participants (75.0%) were female and 100 (100.0%) were Asian. Medication compliance was checked during participant interviews and by counting excess tablets. At week 12, the improvement rate was 38.0% (19 of 50) in the doxycycline group and 16.0% (8 of 50) in the placebo group (difference, 22.0%; 95% CI, 5.0-39.0; P = .01) in the intention-to-treat population. The per-protocol sensitivity analysis showed similar results (39.6% [19 of 48] vs 16.0% [8 of 50]; difference, 23.6%; 95% CI, 6.4-40.8; P = .009). No adverse events other than 1 case of mild gastric acid regurgitation was recorded in either group. CONCLUSIONS AND RELEVANCE: The results of this study indicate that oral doxycycline, 50 mg daily, resulted in greater improvement of TAO-related symptoms at 12 weeks compared with placebo in patients with mild TAO. These findings support the consideration of doxycycline for mild TAO but should be tempered by recognizing the relatively short follow-up and the size of the cohort. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02203682.
引用
- Pan Y, Chen YX, Zhang J, et al. Doxycycline vs Placebo at 12 Weeks in Patients With Mild Thyroid-Associated Ophthalmopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2022. PMID: 36173609. doi:10.1001/jamaophthalmol.2022.3779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。